Santhera valuation report "On steroids - but better!"

Tuesday, June 4, 2024 @ 12:00 am

AGAMREE is off to a flying start in the US and EU, with initial sales surpassing expectations. We forecast global peak sales of CHF 750+ mn, which would be transformational. Santhera guides for a cash reach into 2025 (excluding maturing convertible bonds) and expects to reach breakeven on a cash basis by H1 2026.

Key catalysts include:

1. AGAMREE UK launch in DMD (summer 2024)
2. AGAMREE partnerships (during 2024)
3. AGAMREE China approval; launch in France, Italy, Spain, Benelux (Q1 2025)

Santhera Valuation Report

You may also be interested in

Beware of fraudulent emails impersonating the Swiss Biotech Association

Don’t fall for fraudsters! Cyber criminals can reach you easily with today's communication means. We recently noticed fraudulent emails to steal your passwords of your Microsoft, Outlook or similar accounts via phishing emails. Smishing (SMS, text messages) or vishing (phone calls) are also a common way to retrieve information from you. With seemingly legitimate messages the criminals will ask y
October 8, 2024

LimmaTech awarded FDA fast track designation for vaccine against Staphylococcus aureus

LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to LimmaTech’s multivalent toxoid vaccine candidate, LBT-SA7, designed to prevent skin and soft tissue infections (SSTIs) caused by the bacterial pathogen, Staphylococcus a
December 19, 2024

Vandria becoming clinical stage company: First clinical trial for neurodegenerative disorders

Vandria SA, a company at the vanguard of mitochondrial therapeutics developing first-in-class small molecule mitophagy inducers, today announces that the first subjects have been dosed in its first-in-human clinical trial of its lead Central Nervous System (CNS) compound VNA-318. Readout of this combined single and multiple ascending dose trial is expected in the summer of 2025.
December 18, 2024

BioCopy's CEO Matthias Wiedenfels among Germany's biotech pioneers of the coming decade

BioCopy CEO Matthias Wiedenfels honored as winner of "Germany's 30 by 2030" award.
December 17, 2024

The co-founders of AlphaMol are ranked as the "top 2% scientists" in the world

December 16, 2024

Porton Pharma Solutions: Collaboration with Aojin Life Sciences in China and USA

December 13, 2024